Oriental Congress of Cardiology (OCC) report now available
Founded in 1974, the International Aspirin Foundation shares information and stimulates research interest and discussion about all aspects of aspirin and acetylsalicylic acid.
Scientific Advisory Board
Key Features
Scientific Conference
A report of proceedings from the International Aspirin Foundation’s (IAF) first ever symposium in China at the 2021 Oriental Congress of Cardiology (OCC) is now available.
Focusing on the use of low-dose aspirin for the prevention of atherothrombosis across the cardiovascular risk continuum, the report covers both the presentations and discussions between experts from China, Europe and USA.
Professor Junbo Ge, President of OCC and Scientific Advisory Board member of IAF, was delighted to host the symposium to provide information and knowledge from world leading experts.
A copy of the report is available here. The full presentations can be viewed here.
The International Aspirin Foundation’s next Scientific Conference will celebrate 125 years of aspirin.
This will be a hybrid event which will reflect on past and future innovations.
More details will be shared soon.
International Aspirin Foundation scientific advisory board member Professor Lina Badimon pays tribute to our Senior Science Award 2020 recipients and reflects on her own career and ongoing interest in the use of low-dose aspirin as precision medicine. In conversation with health journalist Pennie Taylor, the Barcelona-based cardiovascular specialist discusses her work with UNESCO/UNITWIN where she has the Chair on Biomedical Sciences Training and Research, and the Balkan countries’ registry that is investigating aspirin for primary prevention. Powerfully, Professor Badimon also shares her views on the fast-changing role of women in science, an area for which she holds responsibility on the board of the European Society of Cardiology.
Contributions from the research community shared here are unsolicited and are not peer reviewed. We encourage sharing information and stimulating research interest, but we do not endorse or approve the submission. See full disclaimer
Mervyn Vergouwen, MD PhD,
Professor Mazzeffi.
Prof van Gijn discussed the optimal aspirin dose to reduce the risk of TIA’s or non-disabling brain ischaemia which led to the Dutch TIA trial. The trial proved 30mg was equal to 300mg in efficacy.
Sign up to be part of the aspirin community and be the first to receive latest information.
Have something to say about aspirin?
Have something to say about aspirin?
Please fill in the form below and we will contact you with further information.
Have something to say about aspirin?
We would like to hear from you and have a chat, and maybe feature you on our podcast. Please fill in the form below and we will contact you with further information.
Adjunct Associate Professor DUKE-NUS Graduate Medical School,
Consultant Oncologist Curie Oncology Singapore,
Visiting Consultant National Cancer Centre Singapore.
Medical Oncology
In the past 3 years, I have received consultant fees from Tessa Therapeutics, Aslan Pharmaceuticals, Novartis, and AstraZeneca.
I received grant support for investigator-initiated research from:
I hold shares in: Roche, BMS, AstraZeneca, Incyte, Teva Pharmaceuticals, Trillium Therapeutics, Compugen, Arrowhead pharmaceuticals, Emergex, QuantumDx and Halozyme Therapeutics
I received consultant and speakers fees from Amgen, AstraZeneca, Bayer, Lilly and Sanofi.
Junbo Ge
Ge Junbo, male, was born in Wulian, Shandong province on Nov. 8, 1962. He is the member of Chinese Academy of Sciences, professor and doctoral supervisor. He received his doctor’s degree of Medicine from German Mayence University in 1993 and now works as the director for Shanghai Institute of Cardiovascular Disease and the Center for Stem Cells and Tissue Engineering, Fudan University. He is also the designate chairman of the Cardiovascular Disease Branch of Chinese Medical Association, council member of the Cardiovascular Angiography and Interventions Association, international consultant of the American Heart Association. In Dec. 2013, he was appointed as the vice president of Tongji University.
Prof. Ge has been engaged in clinical and scientific research work of cardiovascular disease since 1987, and his research area covers the pathogenesis of coronary heart disease, early diagnosis and treatment plan optimization.
AACR Honors Dr. Andrew T. Chan With 2019 AACR-Waun Ki Hong Award
Click here to find the press release.
I received consultant Bayer and Pfizer, Inc.
I received grant support for investigator-initiated research from:
Professor of Medicine, Harvard Medical School; Chief Division of Aging, Brigham and Women’s Hospital; Director of Preventive Cardiology and Director of Massachusetts Veterans Epidemiology Research and Information Center (MAVERIC), VA Boston Healthcare System.
Discipline: Cardiology and Epidemiology
I received consultant and speaker fees Bayer.
I received grant support as a principal investigator or co-investigator for research from the VA, DOD, NIH, Merck and Kowa.
Pierre Amarenco, MD, FAHA, FAAN
Neurology and Vascular Neurology
N/A
I received consultant and speakers fees from Acticor Biotech, Amgen, Bayer, GlaxoSmithKline, Tremeau, Zambon.
I received grant support for investigator-initiated research from: